Read the latest drug news in dermatology, and browse related topics here.
 
 
Azelaic acid foam reenters the market
LEO Pharma announces azelaic acid foam 15% (Finacea) is now available on the market to treat inflammatory papules and pustules of mild-to-moderate rosacea.
 
Novel drug in development for AD, asthma
LEO Pharma has entered into a license agreement with Oneness Biotech and Microbio Shanghai for the development and commercialization of the investigational drug FB825 for the treatment of atopic dermatitis and asthma.
 
Ixekizumab approved for pediatric patients
Eli Lilly announces the U.S. Food and Drug Administration approval of ixekizumab (Taltz) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6 and under 18 who are also eligible for phototherapy and systemic therapy.
 

Connect with us on Twitter and Facebook for daily updates.
 
ADVERTISEMENT
Atopic dermatitis: identifying causes of inflammation
Why is it so difficult to pinpoint reasons for inflammation in patients who develop atopic dermatitis? In this Dermatology Times®podcast, Peter Lio, MD, provides in-depth analyses of both the "immune dysfunction" hypothesis and the "barrier defect" hypothesis. Listen to the podcast now.
 
 
From our Latest Issue
 
Dermatology Times cover
Novel topical foam promising for papulopustular rosacea
 
COVID-19 pandemic requires vigilance, not panic
 
Education key to optimizing care of rosacea patients